Neuropeptide Y receptor antagonists.

Area of Science:

• Pharmacology
• Medicinal Chemistry
• Neuroscience

Background:

• Neuropeptide Y (NPY) plays a role in regulating food intake and energy balance.
• NPY receptor subtypes Y(1) and Y(5) are key targets for anti-obesity drug development.
• Patent literature provides insights into the chemical entities developed as NPY antagonists.

Purpose of the Study:

• To review patent literature on neuropeptide Y (NPY) antagonists from January 2000 to March 2001.
• To focus on antagonists targeting Y(1) and Y(5) receptor subtypes.
• To assess the landscape of NPY antagonist development for anti-obesity applications.

Main Methods:

• Comprehensive review of patent literature.
• Analysis of claimed chemical entities as antagonists for Y(1) and Y(5) receptors.
• Comparison of the number and nature of antagonists for each receptor subtype.

Main Results:

• A limited number of new chemical entities were patented as Y(1) receptor antagonists compared to Y(5) receptor antagonists.
• Subnanomolar antagonists selective for both Y(1) and Y(5) receptor subtypes have been developed.
• The patent landscape suggests a potential greater interest or challenges in developing Y(1) specific antagonists.

Conclusions:

• The development of Y(5) receptor antagonists appears more advanced than Y(1) receptor antagonists in the patent literature.
• Selective Y(1) and Y(5) receptor antagonists are available for further investigation into their physiological roles.
• These antagonists hold potential for understanding and treating obesity and related metabolic disorders.